新型冠状病毒病2019大流行应对头两年英格兰西南部大肠埃希菌血流感染抗菌药物耐药趋势的流行病学
该研究对2016至2021年英国卫生安全局监测的英格兰西南部大肠埃希菌血流感染病例进行回顾性生态学分析,采用贝叶斯分段回归评估2020年3月23日COVID-19限制措施实施前后耐药趋势变化。共纳入19055例,限制措施实施时哌拉西林-他唑巴坦和环丙沙星耐药出现即时阶跃变化,庆大霉素和第三代头孢菌素耐药年趋势下降。
要点
- 研究纳入19055例大肠埃希菌血流感染,男性占50.2%,中位年龄76岁(IQR 65-85岁)。
- COVID-19限制实施时哌拉西林-他唑巴坦耐药变化-2.90%(95% HDI -4.51%至-0.48%),环丙沙星耐药变化-2.40%(95% HDI -4.35%至0.48%)。
- 限制实施后庆大霉素耐药年趋势OR 0.92(95% HDI 0.76至1.12),第三代头孢菌素OR 0.95(95% HDI 0.80至1.14),贝叶斯因子分别为5.10和6.67。
核心结论
- COVID-19限制措施导致大肠埃希菌血流感染抗菌药物耐药发生突然且较长期的变化,即时效应提示传播改变,趋势效应可能由耐药大肠埃希菌储库变化解释。
研究设计与样本
- 回顾性生态学分析,利用2016至2021年英国卫生安全局常规监测报告的大肠埃希菌血流感染病例数据。
- 采用贝叶斯分段回归分析COVID-19限制措施(2020年3月23日)实施前后阿莫西林-克拉维酸、环丙沙星、哌拉西林-他唑巴坦、庆大霉素、第三代头孢菌素和碳青霉烯类耐药趋势。
- 共识别19055例病例,男性占50.2%,中位年龄76岁(四分位距65-85岁)。
主要发现
- 哌拉西林-他唑巴坦耐药在COVID-19限制实施时出现即时阶跃变化-2.90%(95%最高密度区间 -4.51%至-0.48%)。
- 环丙沙星耐药在COVID-19限制实施时出现即时阶跃变化-2.40%(95%最高密度区间 -4.35%至0.48%)。
- COVID-19限制实施后庆大霉素耐药年趋势比值比0.92(95%最高密度区间0.76至1.12),第三代头孢菌素耐药年趋势比值比0.95(95%最高密度区间0.80至1.14)。
- 与限制实施前相比,限制实施后庆大霉素耐药比值比降低的贝叶斯因子为5.10,第三代头孢菌素耐药比值比降低的贝叶斯因子为6.67,呈中等证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Between 2016 and 2019, the proportion of Escherichia coli bloodstream infection (BSI) with resistance to at least one antibiotic increased nationally. Public health interventions implemented in response to the COVID-19 pandemic changed population contact patterns and healthcare systems, with consequent effects on epidemiological trends of numerous pathogens. We investigated the impact of COVID-19 restrictions on epidemiological trends of E. coli BSI antimicrobial resistance (AMR) across South West England. METHODS: We undertook a retrospective ecological analysis utilizing routine surveillance data of E. coli BSI cases reported to the UK Health Security Agency between 2016 and 2021. We analysed AMR trends for antimicrobial agents including amoxicillin-clavulanate, ciprofloxacin, piperacillin-tazobactam, gentamicin, third-generation cephalosporins and carbapenems before and after the implementation of COVID-19 restrictions (23 March 2020) using Bayesian segmented regression. RESULTS: We identified 19 055 cases. A total of 50.2% were male. Median age was 76 (interquartile range, 65-85 years). Piperacillin-tazobactam (-2.90% [95% highest density interval {HDI} -4.51%, -0.48%]) and ciprofloxacin (-2.40% [95% HDI -4.35%, 0.48%]) resistance demonstrated immediate step changes at the implementation of COVID-19 restrictions. Gentamicin (odds ratio [OR] 0.92 [95% HDI 0.76, 1.12]) and third-generation cephalosporins (OR 0.95 [95% HDI 0.80, 1.14]) exhibited decreasing annual resistance trends after the implementation of COVID-19 restrictions, with moderate evidence for a lower OR after restrictions as compared to the period before (gentamicin Bayes Factor = 5.10, third-generation cephalosporins Bayes Factor = 6.67). DISCUSSION: COVID-19 restrictions led to abrupt and longer term changes to E.coli BSI AMR. The immediate effects suggest altered transmission, whereas changes to resistant E. coli reservoirs may explain trend effects.
引用
- Stanley J, Sullivan B, Dowsey AW, et al. Epidemiology of Escherichia coli bloodstream infection antimicrobial resistance trends across South West England during the first 2 years of the coronavirus disease 2019 pandemic response. Clin Microbiol Infect. 2024. PMID: 38527612. doi:10.1016/j.cmi.2024.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。